CYT-501

N/A

Report date: 2022/09/05 16:52:03

Base Information

Drug NameCYT-501
Drug Alias NameCYT-501CYTO-NK-205
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacementsAnti-Epidermal growth factor receptor erbB1
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCytoImmune Therapeutics IncCytovia Inc
China Registration ClassN/A

Develop Information

Active CompaniesCytoImmune Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A